N@N

BioMedReports.com: Oculus Innovative Sciences' CEO Reaffirms Plans for New Markets and Greater Profits During Interview (Nasdaq

_{//health-fitness.news-articles.net/content/2009/ .. and-greater-profits-during-interview-nasdaq.html}
^{Published in Health and Fitness on Thursday, August 20th 2009 at 12:29 GMT, Last Modified on 2009-08-20 12:29:10 by Market Wire}  

LOS ANGELES, CA--(Marketwire - August 20, 2009) - BioMedReports, the leading news portal which covers the publicly traded biomedical and pharmaceutical companies of the financial markets, has released a special report and interview with Hoji Alimi, the CEO and Founder of Oculus Innovative Sciences, Inc. (NASDAQ: [ OCLS ]).

The biopharmaceutical company based in California develops, manufactures and markets its Microcyn® platform technology which helps prevent and treat infections in chronic and acute wounds.

The company's innovative products have been gaining the attention of Wall Street and the national media as well as doctors and hospitals due to their rapid kill anti-microbial properties. The FDA granted Oculus an expanded 510(k) label clearance for their product and according to the company's CEO, new marketing efforts and partnerships in the U.S. and China, will help them expand the customer base, thus growing profits significantly.

"The way informed investors see it, thousands of doctors and their patients would probably not be adopting Microcyn® products as their standard of care for treating various maladies including wounds, diabetic foot ulcers, and burns if they weren't safe and didn't work," says Peter Depalma, who writes for BioMedReports. "As a company, Oculus has shown strong leadership and innovation and newly released details about their marketing plans in countries like the U.S. and China point to some great opportunities."

The science behind Microcyn® establishes it as a non-irritating compound designed to treat a range of pathogens in wounds, including viruses, fungi, spores and antibiotic-resistant strains of bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA), and Vancomycin-resistant Enterococcus (VRE).

The new special report and a candid audio interview with the company's CEO are now available at BioMedReports.com:

[ http://biomedreports.com/articles/most-popular/6320-ceo-reaffirms-market-and-profit-growth-plans-for-oculus-innovative-sciences-nasdaq-ocls.html ]

Biotech investors interested in accessing BioMedReports' exclusive and complete database of clinical trials and upcoming FDA decisions can access it at:

[ http://biomedreports.com/fda-calendar/fda-calendar.html ]